Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. Class A Common Stock

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. 

Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. 

For more information, visit tempus.com and follow us on Twitter (@TempusLabs). 

Tempus AI

Our founder and CEO, Eric Lefkofky, joins mHUB for next week's HardTech Summit to discuss his path to #AI enabled healthcare. Register here: https://tempus.co/4c2W6Q2 

Dr. Ezra Cohen’s personal passion for taking care of cancer patients led him from decades of clinical care and research to Tempus as our Chief Medical Officer of Oncology. In our #TempusWhy series, Dr. Cohen shares how our work at Tempus fuels his unwavering commitment and determination to advancing cancer care. 

Hear more: 

Physicians like Dr. James and their care teams seamlessly use Tempus One to make informed patient treatment decisions through convenient functionalities that deliver insights on patient’s full clinical and molecular profile. By improving clinical workflows, One can allow more time for teams to focus on patient care. Learn more about Tempus One: https://tempus.co/42ZDYT4 

We’re looking forward to being on-site this week at the Liquid Biopsy for Precision Oncology Summit. Attend Adam Morabito’s presentation on how emerging technologies and multi-modal data have unlocked novel use cases for tumor-naïve liquid biopsies. Learn more: https://tempus.co/4bIlHha 

We’re #NowHiring for a Territory Sales Executive to join our team in North Atlanta. This position will drive new opportunities with major US cancer centers, clinics, and oncology practices. Join our growing sales team by applying here: https://bit.ly/3T6HkjX #atljobs 

msh id	COM:TEMPUS
symbol	TEM
name	Tempus AI, Inc. Class A Common Stock
homepage url	https://www.tempus.com
country	US
sector	Healthcare
industry	Healthcare
market	STOCKS
employee count	-
crunchbase url	-
linkedin url	-
founders	-

market cap	5.77B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	158.51K
monthly webtraffic growth	2.47
growth score 14	28.59
growth score 28	50.87
growth score 90	48.17
growth score 365	43.28

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

TEM

COM:TEMPUS

Tempus

Last Close

58.15

21/11 21:00

Market Cap

5.77B

Beta: -

Volume Today

1.73M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-